| Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ... JAMA oncology 4 (2), 173-182, 2018 | 973 | 2018 |
| Wnt/beta-catenin pathway: modulating anticancer immune response SG Pai, BA Carneiro, JM Mota, R Costa, CA Leite, R Barroso-Sousa, ... Journal of hematology & oncology 10, 1-12, 2017 | 571 | 2017 |
| Endocrine toxicity of cancer immunotherapy targeting immune checkpoints LS Chang, R Barroso-Sousa, SM Tolaney, FS Hodi, UB Kaiser, L Min Endocrine reviews 40 (1), 17-65, 2019 | 453 | 2019 |
| Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis PG Czaikoski, JMSC Mota, DC Nascimento, F Sônego, FVS Castanheira, ... PloS one 11 (2), e0148142, 2016 | 368 | 2016 |
| Prevalence and mutational determinants of high tumor mutation burden in breast cancer R Barroso-Sousa, E Jain, O Cohen, D Kim, J Buendia-Buendia, E Winer, ... Annals of Oncology 31 (3), 387-394, 2020 | 287 | 2020 |
| Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice LF Campesato, R Barroso-Sousa, L Jimenez, BR Correa, J Sabbaga, ... Oncotarget 6 (33), 34221, 2015 | 237 | 2015 |
| Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy H Lee, FS Hodi, A Giobbie-Hurder, PA Ott, EI Buchbinder, R Haq, ... Cancer Immunology Research 5 (12), 1133-1140, 2017 | 146 | 2017 |
| Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications R Barroso-Sousa, O Metzger-Filho Therapeutic advances in medical oncology 8 (4), 261-266, 2016 | 145 | 2016 |
| Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer R Barroso-Sousa, TE Keenan, S Pernas, P Exman, E Jain, ... Clinical cancer research 26 (11), 2565-2572, 2020 | 144 | 2020 |
| Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche P Baldominos, A Barbera-Mourelle, O Barreiro, Y Huang, A Wight, ... Cell 185 (10), 1694-1708. e19, 2022 | 121 | 2022 |
| Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer R Barroso-Sousa, GI Shapiro, SM Tolaney Breast care 11 (3), 167-173, 2016 | 114 | 2016 |
| Sleep disturbances in patients on maintenance hemodialysis: role of dialysis shift JPC Bastos, RB Sousa, LAM Nepomuceno, OA Gutierrez-Adrianzen, ... Revista da Associação Médica Brasileira 53, 492-496, 2007 | 106 | 2007 |
| Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management R Barroso‐Sousa, PA Ott, FS Hodi, UB Kaiser, SM Tolaney, L Min Cancer 124 (6), 1111-1121, 2018 | 105 | 2018 |
| Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2-negative metastatic breast cancer: A randomized … SM Tolaney, R Barroso-Sousa, T Keenan, T Li, L Trippa, I Vaz-Luis, ... JAMA oncology 6 (10), 1598-1605, 2020 | 103 | 2020 |
| Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer AC Garrido-Castro, C Saura, R Barroso-Sousa, H Guo, E Ciruelos, ... Breast Cancer Research 22, 1-13, 2020 | 73 | 2020 |
| Optimal treatment of early stage HER2‐positive breast cancer S Pernas, R Barroso‐Sousa, SM Tolaney Cancer 124 (23), 4455-4466, 2018 | 63 | 2018 |
| Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia GC De Santis, M de Barros Tamarozzi, RB Sousa, SE Moreno, D Secco, ... haematologica 92 (12), 1615-1622, 2007 | 56 | 2007 |
| Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster RFC Leitão, RA Ribeiro, AMS Lira, LR Silva, EAL Bellaguarda, ... Cancer chemotherapy and pharmacology 61, 215-222, 2008 | 55 | 2008 |
| Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib LG Da Fonseca, R Barroso-Sousa, ASA Bento, BP Blanco, GL Valente, ... Medical oncology 31, 1-6, 2014 | 52 | 2014 |
| Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward CH Barrios, G Werutsky, A Mohar, AS Ferrigno, BG Müller, BL Bychkovsky, ... The Lancet Oncology 22 (11), e474-e487, 2021 | 50 | 2021 |
